Adrenal Insufficiency Market Report: 2016 Edition
Adrenal Insufficiency is a rare disease in which the adrenal glands are unable to produce sufficient amount of the hormones cortisone, aldosterone or Dehydroepiandrosterone, which are essential for vital functions of the human body. Cortisol in particular is very important for life and its deficiency can lead to the inability of the body to cope with intense stress. This condition can be life threatening, the sudden and severe worsening of which is called adrenal crisis. Common symptoms of adrenal insufficiency are fatigue, muscle weakness, loss of appetite, weight loss, and abdominal pain.
Adrenal insufficiency can be of two types, namely primary or secondary adrenal insufficiency. Primary adrenal insufficiency, also called Addison’s disease occurs when the adrenal glands cannot produce sufficient amount of the adrenal hormone cortisol or aldosterone. Secondary adrenal insufficiency occurs when the pituitary gland is unable to produce enough amount of adrenocorticotropic hormone (ACTH), the lack of which drops cortisol production resulting in the shrinkage of adrenal glands. The most common cause of adrenal insufficiency is autoimmune diseases like rheumatoid arthritis, pernicious anemia and lupus erythematosus etc., while infections like tuberculosis are also known to cause the disease. It can be diagnosed through tests like Hormonal Blood and Urine Tests.
The entire adrenal insufficiency market can be subdivided into the market for pediatric and adult insufficiency, the latter of which constitutes a massive share. Further, cortisol deficiency records higher prevalence and market among other adrenal hormones. The Adrenal Insufficiency market is characterized by few competitors, specialist providers and known patient groups which are driven by factors like escalating healthcare spending, increasing sales of prescription drugs, rising spending on medicines and growing market for orphan drugs. In recent years, treatment market of this disease has been witnessing increased medical research for alternative therapies like transplantation of adrenal glands. However, symptoms of the disease are often ignored, leaving the market largely underdiagnosed.
The report “Adrenal Insufficiency Market” analyzes the development of this market, with focus on the United States and Europe. Major trends, growth drivers as well as issues being faced by the industry are discussed in detail in the report along with the present and upcoming competition in the market.
Adrenal insufficiency can be of two types, namely primary or secondary adrenal insufficiency. Primary adrenal insufficiency, also called Addison’s disease occurs when the adrenal glands cannot produce sufficient amount of the adrenal hormone cortisol or aldosterone. Secondary adrenal insufficiency occurs when the pituitary gland is unable to produce enough amount of adrenocorticotropic hormone (ACTH), the lack of which drops cortisol production resulting in the shrinkage of adrenal glands. The most common cause of adrenal insufficiency is autoimmune diseases like rheumatoid arthritis, pernicious anemia and lupus erythematosus etc., while infections like tuberculosis are also known to cause the disease. It can be diagnosed through tests like Hormonal Blood and Urine Tests.
The entire adrenal insufficiency market can be subdivided into the market for pediatric and adult insufficiency, the latter of which constitutes a massive share. Further, cortisol deficiency records higher prevalence and market among other adrenal hormones. The Adrenal Insufficiency market is characterized by few competitors, specialist providers and known patient groups which are driven by factors like escalating healthcare spending, increasing sales of prescription drugs, rising spending on medicines and growing market for orphan drugs. In recent years, treatment market of this disease has been witnessing increased medical research for alternative therapies like transplantation of adrenal glands. However, symptoms of the disease are often ignored, leaving the market largely underdiagnosed.
The report “Adrenal Insufficiency Market” analyzes the development of this market, with focus on the United States and Europe. Major trends, growth drivers as well as issues being faced by the industry are discussed in detail in the report along with the present and upcoming competition in the market.
1. MARKET OVERVIEW
1.1 Introduction
1.1.1 Cortisol Insufficiency
1.1.2 Aldosterone Insufficiency
1.1.3 Dehydroepiandrosterone Insufficiency
1.2 Symptoms
1.2.1 Adrenal Insufficiency
1.2.2 Adrenal Crisis
1.3 Causes
1.3.1 Primary Adrenal Insufficiency
1.3.2 Secondary Adrenal Insufficiency
1.4 Prevention
1.5 Diagnosis
1.5.1 Hormonal Blood and Urine Tests
1.5.2 Test for Adrenal Crisis
1.6 Treatment Options
2. GLOBAL ADRENAL INSUFFICIENCY MARKET
2.1 Global Adrenal Insufficiency Prevalence
2.2 Global Adrenal Insufficiency Market by Value
2.3 Global Adrenal Insufficiency Prevalence by Type
2.4 Global Adrenal Insufficiency Market by Region
2.4.1 Global Adrenal Insufficiency Prevalence by Region
2.4.2 Global Adrenal Insufficiency Market Value by Region
3. REGIONAL MARKETS
3.1 The U.S. Cortisol Deficiency Market
3.1.1 Pediatric Cortisol Deficiency Prevalence
3.1.2 Pediatric Cortisol Deficiency Market by Value
3.1.3 Adult Cortisol Deficiency Prevalence
3.1.4 Adult Cortisol Deficiency Market by Value
3.2 EU5 Cortisol Deficiency Market
3.2.1 Pediatric Cortisol Deficiency Market by Prevalence
3.2.2 Pediatric Cortisol Deficiency Market by Value
3.2.3 Adult Cortisol Deficiency Market by Prevalence
3.2.4 Adult Cortisol Deficiency Market by Value
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Escalating Healthcare Spending
4.1.2 Increasing Sales of Prescription Drugs
4.1.3 Rising Incidence of Autoimmune Disease
4.1.4 Rising Spending on Medicines
4.1.5 Increasing Female Population
4.1.6 Growing Market for Orphan Drugs
4.2 Trends
4.2.1 Oral Glucocorticoid Replacement
4.2.2 Transplantation of Adrenal Glands
4.2.3 Alternate Therapies
4.2.4 Chronic Heroin Dependence as a Cause
4.3 Challenges
4.3.1 Underdiagnosed Disease
4.3.2 Symptoms Often Ignored
5. COMPETITIVE LANDSCAPE
5.1 Adrenal Insufficiency Upcoming Competition by Sales
5.2 Adrenal Insufficiency Market Cap Comparison
6. COMPANY PROFILES
6.1 Bristol Myers Squibb
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Novartis
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Pfizer Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 StrongBridge Biopharma
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
1.1 Introduction
1.1.1 Cortisol Insufficiency
1.1.2 Aldosterone Insufficiency
1.1.3 Dehydroepiandrosterone Insufficiency
1.2 Symptoms
1.2.1 Adrenal Insufficiency
1.2.2 Adrenal Crisis
1.3 Causes
1.3.1 Primary Adrenal Insufficiency
1.3.2 Secondary Adrenal Insufficiency
1.4 Prevention
1.5 Diagnosis
1.5.1 Hormonal Blood and Urine Tests
1.5.2 Test for Adrenal Crisis
1.6 Treatment Options
2. GLOBAL ADRENAL INSUFFICIENCY MARKET
2.1 Global Adrenal Insufficiency Prevalence
2.2 Global Adrenal Insufficiency Market by Value
2.3 Global Adrenal Insufficiency Prevalence by Type
2.4 Global Adrenal Insufficiency Market by Region
2.4.1 Global Adrenal Insufficiency Prevalence by Region
2.4.2 Global Adrenal Insufficiency Market Value by Region
3. REGIONAL MARKETS
3.1 The U.S. Cortisol Deficiency Market
3.1.1 Pediatric Cortisol Deficiency Prevalence
3.1.2 Pediatric Cortisol Deficiency Market by Value
3.1.3 Adult Cortisol Deficiency Prevalence
3.1.4 Adult Cortisol Deficiency Market by Value
3.2 EU5 Cortisol Deficiency Market
3.2.1 Pediatric Cortisol Deficiency Market by Prevalence
3.2.2 Pediatric Cortisol Deficiency Market by Value
3.2.3 Adult Cortisol Deficiency Market by Prevalence
3.2.4 Adult Cortisol Deficiency Market by Value
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Escalating Healthcare Spending
4.1.2 Increasing Sales of Prescription Drugs
4.1.3 Rising Incidence of Autoimmune Disease
4.1.4 Rising Spending on Medicines
4.1.5 Increasing Female Population
4.1.6 Growing Market for Orphan Drugs
4.2 Trends
4.2.1 Oral Glucocorticoid Replacement
4.2.2 Transplantation of Adrenal Glands
4.2.3 Alternate Therapies
4.2.4 Chronic Heroin Dependence as a Cause
4.3 Challenges
4.3.1 Underdiagnosed Disease
4.3.2 Symptoms Often Ignored
5. COMPETITIVE LANDSCAPE
5.1 Adrenal Insufficiency Upcoming Competition by Sales
5.2 Adrenal Insufficiency Market Cap Comparison
6. COMPANY PROFILES
6.1 Bristol Myers Squibb
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Novartis
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Pfizer Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 StrongBridge Biopharma
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
LIST OF CHARTS
Global Adrenal Insufficiency Prevalence (2015)
Global Adrenal Insufficiency Market by Value (2015)
Global Adrenal Insufficiency Prevalence by Type (2015)
Adrenal Insufficiency Prevalence by Region (2015)
Global Adrenal Insufficiency Market Value by Region (2015)
The U.S. Pediatric Cortisol Deficiency Prevalence (2015)
The U.S. Pediatric Cortisol Deficiency Market by Value (2015)
The U.S. Adult Cortisol Deficiency Prevalence (2015)
The U.S. Adult Cortisol Deficiency Market by Value (2015)
The EU5 Pediatric Cortisol Deficiency by Prevalence (2015)
The EU5 Pediatric Cortisol Deficiency by Value (2015)
The EU5 Adult Cortisol Deficiency by Prevalence (2015)
The EU5 Adult Cortisol Deficiency Market by Value (2015)
Global Healthcare Spending (2007-2015E)
Global Sales of Prescription Drugs (2010-2015E)
Rheumatoid Arthritis Prevalence in the U.S. (2015-2020E)
Global Spending on Medicines (2010-2020E)
Global Female Population (2009-2015)
Global Orphan Drugs Market (2010-2015E)
Bristol Myers Revenue Share by Region (2015)
Bristol Myers Revenue and Net Income (2011-2015)
Novartis Revenue by Business Segments (2015)
Novartis Revenue and Net Income (2012-2015)
Pfizer Revenue Share by Business Segments (2015)
Pfizer Revenue and Net Income (2011-2015)
StrongBridge BioPharma Revenue and Net Income (2018E-2025E)
Global Adrenal Insufficiency Prevalence (2015)
Global Adrenal Insufficiency Market by Value (2015)
Global Adrenal Insufficiency Prevalence by Type (2015)
Adrenal Insufficiency Prevalence by Region (2015)
Global Adrenal Insufficiency Market Value by Region (2015)
The U.S. Pediatric Cortisol Deficiency Prevalence (2015)
The U.S. Pediatric Cortisol Deficiency Market by Value (2015)
The U.S. Adult Cortisol Deficiency Prevalence (2015)
The U.S. Adult Cortisol Deficiency Market by Value (2015)
The EU5 Pediatric Cortisol Deficiency by Prevalence (2015)
The EU5 Pediatric Cortisol Deficiency by Value (2015)
The EU5 Adult Cortisol Deficiency by Prevalence (2015)
The EU5 Adult Cortisol Deficiency Market by Value (2015)
Global Healthcare Spending (2007-2015E)
Global Sales of Prescription Drugs (2010-2015E)
Rheumatoid Arthritis Prevalence in the U.S. (2015-2020E)
Global Spending on Medicines (2010-2020E)
Global Female Population (2009-2015)
Global Orphan Drugs Market (2010-2015E)
Bristol Myers Revenue Share by Region (2015)
Bristol Myers Revenue and Net Income (2011-2015)
Novartis Revenue by Business Segments (2015)
Novartis Revenue and Net Income (2012-2015)
Pfizer Revenue Share by Business Segments (2015)
Pfizer Revenue and Net Income (2011-2015)
StrongBridge BioPharma Revenue and Net Income (2018E-2025E)
LIST OF TABLES
Adrenal Insufficiency Upcoming Competition Sales Comparison (2015)
Adrenal Insufficiency Market Cap Comparison (2015)
StrongBridge Product Portfolio
Adrenal Insufficiency Upcoming Competition Sales Comparison (2015)
Adrenal Insufficiency Market Cap Comparison (2015)
StrongBridge Product Portfolio
